CCM
RANI icon

CAAS Capital Management’s Rani Therapeutics RANI Stock Holding History

CAAS Capital Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-13,934
Closed -$228K – 881
2021
Q4 		$228K Sell
13,934
-61,066
-81% -$1.39M 0.01% 649
2021
Q3 		$1.34M Buy
+75,000
New +$1.3M 0.03% 427

Other funds holding RANI

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ASGS
Alpha Square Group S New York $103M AUM 63.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CAAS Capital Management's RANI Position: Q1 2022 in Review

CAAS Capital Management sold out of Rani Therapeutics (RANI) in Q1 2022, closing a stake of 13,934 shares — an estimated $228K sold.

CAAS Capital Management first reported a position in RANI in Q3 2021 and held it in 2 quarters. The position peaked at $1.34M in Q3 2021. 24 funds tracked by Wall St. Rank hold RANI as of Q1 2022.

  • CAAS Capital Management reported no remaining Rani Therapeutics position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 13,934 Rani Therapeutics shares in Q1 2022, an estimated $228K.
  • CAAS Capital Management first reported a position in Rani Therapeutics in Q3 2021 and held it in 2 quarters.
  • CAAS Capital Management's Rani Therapeutics position peaked at $1.34M in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.